ESK-001 for Plaque Psoriasis

Recruiting in Palo Alto (17 mi)

+39 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Alumis Inc

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial involves patients with plaque psoriasis who have already participated in a previous study of ESK-001. They will continue to receive ESK-001 to see if it helps reduce their symptoms. The study will last for an extended period.

Research Team

Eligibility Criteria

This trial is for men and women with plaque psoriasis who have finished a previous study involving ESK-001. Participants must commit to using effective contraception throughout the study. Pregnant individuals or those on certain other medications cannot join.

Inclusion Criteria

I will use effective birth control during the study.

Must have completed a prior ESK-001 study

Exclusion Criteria

I have not taken any medication that is not allowed in the study.

Pregnancy

Treatment Details

Interventions

ESK-001 (Biologic Response Modifier)

Trial OverviewThe trial is testing the long-term safety and effectiveness of a medication called ESK-001 in treating plaque psoriasis. It's an open-label extension, meaning everyone knows they're getting ESK-001, and it involves multiple centers.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: ESK-001 Dose Level 2Experimental Treatment1 Intervention

ESK-001 administered as an oral tablet

Group II: ESK-001 Dose Level 1Experimental Treatment1 Intervention

ESK-001 administered as an oral tablet